Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug... ( CRANBURY N.J. Dec. 1 /- Palatin T...)

Palatin Technologies, Inc. Issued U.S. Patent for Heart Failure Drug Candidate

Date:12/1/2009

CRANBURY, N.J., Dec. 1 /PRNewswire-FirstCall/ -- Palatin Technologies, Inc. (NYSE Amex: PTN) today announced that the U.S. Patent and Trademark Office has issued U.S. Patent No. 7,622,440, titled "Cyclic Natriuretic Peptide Constructs." The claims in the issued patent cover a family of cyclic compounds that bind to natriuretic peptide receptor A (NPRA), including PL-3994, Palatin's lead heart failure drug candidate.

"Our natriuretic compounds, including PL-3994, address significant unmet medical needs," said Trevor Hallam, Ph.D., Palatin's Executive Vice President - Research and Development. "These are the only reported compounds that bind to NPRA and have extended half-lives and pharmacokinetic properties making daily subcutaneous administration possible. Besides the potential to decrease re-hospitalization rates in patients with heart failure, PL-3994 may also have application in treating resistant hypertension and pulmonary arterial hypertension."

PL-3994 and the related family of cyclic compounds were discovered and developed by Palatin scientists and are solely owned by Palatin. In addition to this issued U.S. patent, Palatin has applications pending in selected countries outside the United States and additional U.S. applications covering related compounds.

About PL-3994

Palatin has completed two clinical trials with PL-3994, a Phase 1 trial in healthy volunteers and a Phase 2a trial in patients with controlled hypertension. PL-3994 produced dose-related decreases in blood pressure, increases in plasma cGMP (cyclic guanosine monophosphate), a natural messenger nucleotide, and increases in urine volume and sodium excretion. There were no serious or severe adverse events.

PL-3994 incorporates a novel and proprietary amino acid mimetic developed by scientists at Palatin
'/>"/>

SOURCE Palatin Technologies, Inc.
Copyright©2009 PR Newswire.
All rights reserved

0

GOOD

Post Your Comments:

(Date:5/24/2013)... May 24, 2013 Quincy Bioscience, ... and development of calcium-binding proteins to support healthy ... safety assessment study of apoaequorin in ... published for the British Industrial Biological Research Association. ... to investigate potential adverse effects, if any, of ...

(Date:5/23/2013)... Can economic incentives such as gift cards, T-shirts, ... public to increase their donations of blood? , A ... School Assistant Professor Mario Macis says the answer ... of recent research that supports their argument, the three ... Science that the World Health Organization and national blood ...

(Date:5/23/2013)... The maker community is a contemporary ... They focus on learning practical skills while applying them ... bringing their ideas to life via crowdfunding. A subgroup ... making projects using biology. Glowing Plant has worked for ... them glow with bioluminescence genes, and has now pursued ...

(Date:5/23/2013)... BioTrends Research Group, one of the ... biopharmaceutical issues, finds that, unaided, one in five ... that in the past six months, they have ... anticipation of the next generation of HCV treatments—notably ... 6 percent reported that they had begun warehousing ...

Breaking Biology Technology:Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology 2 Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 2 Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science 3 Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home 2 The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 2 The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments 3

[0] Safety Assessment Study of Apoaequorin Published in Food and Chemical Toxicology [0] Offering Economic Incentives to Attract Blood Donations Should Be Encouraged, Research Team writes in Science [0] Glowing Plant Releases Maker Kit, Enabling Anyone to Make a Glowing Plant at Home [0] The Majority of Physicians that Treat Hepatitis C Virus (HCV) Have Begun "Warehousing" and Preparing Their HCV Patients for the Next Generation of HCV Treatments

... Heritage Labs, a,division of Hooper Holmes (Amex: ... a new at-home consumer product that measures the ... The Appraise(R) Home,A1c Kit provides consumers with an ... and reliable test results equivalent to whole,blood tests ...

... YORK, Aug. 7 Keryx Biopharmaceuticals,Inc. (Nasdaq: KERX ... 11, 2008,at 8:30 a.m. EDT to discuss the second ... Executive Officer of the Company, will,host the call. Keryx ... press release to be issued prior to the call., ...

... (OTC Bulletin Board: GNTA) today announced financial results,for the ... in the second quarter, including the following:, -- ... -- AGENDA Phase 3 trial of Genasense in ... tesetaxel, a leading, clinical-stage oral taxane,lifted by FDA, ...

Hooper Holmes' Heritage Labs Division Launches New Home Diabetes Test Keryx Biopharmaceuticals, Inc. to Hold Conference Call on Second Quarter 2008 Financial Results on Monday, August 11, at 8:30 A.M. EDT Genta Incorporated Announces Second Quarter 2008 Financial Results and Corporate Highlights

(Date:5/23/2013)... mechanism by which estrogen suppresses lipid synthesis in the ... approach toward treating certain liver diseases. , With ... are changing long-held views in the field. Study results ... Science Signaling . , "The dogma in the ... only receptors located in the nucleus respond to steroid ...

(Date:5/23/2013)... Given the implications for the overall health, development, ... a primary role in ensuring that all students ... minutes per day of vigorous or moderate-intensity physical ... of Medicine. Recent estimates suggest that only ... guideline for promoting better health and development. ...

(Date:5/23/2013)... 2013) A new report from the Institute of ... engage in at least 60 minutes of vigorous or ... more than half of American youth meet current evidence-based ... moderate intensity physical activity daily, according to the report, ... in school for nearly half of their waking hours, ...

Breaking Biology News(10 mins):UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis 2 Schools should provide opportunities for 60 minutes of daily physical activity to all students 2 Schools should provide opportunities for 60 minutes of daily physical activity to all students 3 Schools should provide students with daily physical activity, IOM recommends 2

[0] UCI study reveals new mechanism for estrogen suppression of liver lipid synthesis [0] Schools should provide opportunities for 60 minutes of daily physical activity to all students [0] Schools should provide students with daily physical activity, IOM recommends

... 5, 2007) As if being admitted to the ... higher risk of becoming infected with a superbug bacterium, ... difficile kill human intestinal cells by causing them to ... fuel. This results in severe diarrhea and, in rare ...

... dog-walking in bushland significantly reduces bird diversity and ... practice in sensitive bushland and conservation areas. ... impacts of dog-walking have remained subjective and unresolved ... the first clear evidence that birds perceive dogs ...

... know. The supermarket headlines tell us so., Inquiring Texas ... B a tiny, sometimes obscure pest that can damage ... to young cotton for about four weeks," said Dr. ... Lubbock. "They feed on new plant growth, primarily the ...

Cached Biology News:Curbing C. difficile's toxin production 2 A dog in the hand scares birds in the bush 2 Inquiring minds want to know about cotton fleahoppers 2 Inquiring minds want to know about cotton fleahoppers 3

Curbing C. difficile's toxin production A dog in the hand scares birds in the bush Inquiring minds want to know about cotton fleahoppers

Recombinant Equine TNF-alpha/TNFSF1A, CF...

GRADIENT MAKER, 30 ML, 1 EA. Category: Protein Vertical Instruments....

DALT GRADIENT MAKER,230V, 1 EA. Category: 2D DALT Systems....

Rat whole blood (Sprague-Dawley, averaging 7-8 weeks of age, either sex) is collected at the time of slaughter and refrigerated within 6 hours, and processed and frozen within 24 hours. The serum is ...

Biology Products:

Equine TNF-alpha / TNFSF1A, Unconjugated from R&D Systems GRADIENT MAKER, 30 ML from GE Healthcare, formerly Amersham Biosciences DALT GRADIENT MAKER,230V from GE Healthcare, formerly Amersham Biosciences Rat Serum Non-Sterile Trace-Hemolyzed from Pel-Freez Biologicals